Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from InflaRx ( (IFRX) ).
On February 13, 2025, InflaRx N.V. entered into an Underwriting Agreement with Guggenheim Securities, LLC, for a public offering of 8,250,000 ordinary shares and pre-funded warrants to purchase an additional 6,750,000 shares. The offering, closed on February 18, 2025, was priced at $2.00 per share for the ordinary shares, with pre-funded warrants offered at a slightly reduced price due to a nominal exercise fee. The gross proceeds amounted to approximately $30 million, potentially reaching $34.5 million if an option to purchase additional shares is fully exercised. This move is expected to provide InflaRx with significant capital for its operations, potentially enhancing its position in the competitive biotechnology market.
More about InflaRx
InflaRx N.V. is a public limited liability company focused on developing therapeutics in the pharmaceutical industry. The company operates primarily in the biotechnology sector, with a market focus on creating treatments that target inflammatory diseases. InflaRx is headquartered in Jena, Germany.
YTD Price Performance: -20.0%
Average Trading Volume: 357,572
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $117.8M
See more insights into IFRX stock on TipRanks’ Stock Analysis page.
